Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India

Indumathi Manoharan, Stacy Wieseler, Paul G. Layer, Oksana Lockridge, Rathnam Boopathy

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

BACKGROUND: People with genetic variants of butyrylcholinesterase (EC 3.1.1.8, BChE) can have hours of prolonged apnea after a normal dose of succinylcholine or mivacurium. METHODS: Plasma samples from 226 people in the Vysya community in Coimbatore, India were tested for BChE activity. RESULTS: Nine unrelated individuals had no detectable activity. DNA sequencing revealed a novel mutation in exon 2 of the BCHE gene, responsible for the silent phenotype of human serum BChE. All silent BChE samples were homozygous for a point mutation at codon 307 (CTT→CCT), resulting in substitution of leucine 307 by proline. Western blot analysis with a monoclonal antibody showed no BChE protein in plasma. Silent BChE plasma samples had no organophosphate-reactive BChE, as measured with FP-biotin. Expression of recombinant Leu307Pro BChE in cell culture confirmed that this mutant is expressed at very low levels. The proline substitution most likely destabilizes the BChE structure and causes the protein to be misfolded and rapidly degraded. CONCLUSIONS: This is the first report of a molecularly defined BChE mutation in the Indian population. The frequency of homozygous silent BChE in the Vysya community is 1 in 24, a value 4000-fold higher than the frequency of homozygous silent BChE in European and American populations.

Original languageEnglish (US)
Pages (from-to)461-468
Number of pages8
JournalPharmacogenetics and Genomics
Volume16
Issue number7
DOIs
StatePublished - Jul 1 2006

Fingerprint

Butyrylcholinesterase
Proline
India
Mutation
Succinylcholine
Organophosphates
Cholinesterases
Apnea
DNA Sequence Analysis
Point Mutation
Codon
Leucine
Population
Blood Proteins
Exons
Cell Culture Techniques
Western Blotting
Monoclonal Antibodies
Phenotype
Serum

Keywords

  • Apnea
  • Butyrylcholinesterase
  • FP-biotin
  • Mivacurium
  • Silent variant
  • Succinylcholine

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India. / Manoharan, Indumathi; Wieseler, Stacy; Layer, Paul G.; Lockridge, Oksana; Boopathy, Rathnam.

In: Pharmacogenetics and Genomics, Vol. 16, No. 7, 01.07.2006, p. 461-468.

Research output: Contribution to journalArticle

Manoharan, Indumathi ; Wieseler, Stacy ; Layer, Paul G. ; Lockridge, Oksana ; Boopathy, Rathnam. / Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India. In: Pharmacogenetics and Genomics. 2006 ; Vol. 16, No. 7. pp. 461-468.
@article{75b6ac1b1d5f4f94b405225db7a0f0e0,
title = "Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India",
abstract = "BACKGROUND: People with genetic variants of butyrylcholinesterase (EC 3.1.1.8, BChE) can have hours of prolonged apnea after a normal dose of succinylcholine or mivacurium. METHODS: Plasma samples from 226 people in the Vysya community in Coimbatore, India were tested for BChE activity. RESULTS: Nine unrelated individuals had no detectable activity. DNA sequencing revealed a novel mutation in exon 2 of the BCHE gene, responsible for the silent phenotype of human serum BChE. All silent BChE samples were homozygous for a point mutation at codon 307 (CTT→CCT), resulting in substitution of leucine 307 by proline. Western blot analysis with a monoclonal antibody showed no BChE protein in plasma. Silent BChE plasma samples had no organophosphate-reactive BChE, as measured with FP-biotin. Expression of recombinant Leu307Pro BChE in cell culture confirmed that this mutant is expressed at very low levels. The proline substitution most likely destabilizes the BChE structure and causes the protein to be misfolded and rapidly degraded. CONCLUSIONS: This is the first report of a molecularly defined BChE mutation in the Indian population. The frequency of homozygous silent BChE in the Vysya community is 1 in 24, a value 4000-fold higher than the frequency of homozygous silent BChE in European and American populations.",
keywords = "Apnea, Butyrylcholinesterase, FP-biotin, Mivacurium, Silent variant, Succinylcholine",
author = "Indumathi Manoharan and Stacy Wieseler and Layer, {Paul G.} and Oksana Lockridge and Rathnam Boopathy",
year = "2006",
month = "7",
day = "1",
doi = "10.1097/01.fpc.0000197464.37211.77",
language = "English (US)",
volume = "16",
pages = "461--468",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India

AU - Manoharan, Indumathi

AU - Wieseler, Stacy

AU - Layer, Paul G.

AU - Lockridge, Oksana

AU - Boopathy, Rathnam

PY - 2006/7/1

Y1 - 2006/7/1

N2 - BACKGROUND: People with genetic variants of butyrylcholinesterase (EC 3.1.1.8, BChE) can have hours of prolonged apnea after a normal dose of succinylcholine or mivacurium. METHODS: Plasma samples from 226 people in the Vysya community in Coimbatore, India were tested for BChE activity. RESULTS: Nine unrelated individuals had no detectable activity. DNA sequencing revealed a novel mutation in exon 2 of the BCHE gene, responsible for the silent phenotype of human serum BChE. All silent BChE samples were homozygous for a point mutation at codon 307 (CTT→CCT), resulting in substitution of leucine 307 by proline. Western blot analysis with a monoclonal antibody showed no BChE protein in plasma. Silent BChE plasma samples had no organophosphate-reactive BChE, as measured with FP-biotin. Expression of recombinant Leu307Pro BChE in cell culture confirmed that this mutant is expressed at very low levels. The proline substitution most likely destabilizes the BChE structure and causes the protein to be misfolded and rapidly degraded. CONCLUSIONS: This is the first report of a molecularly defined BChE mutation in the Indian population. The frequency of homozygous silent BChE in the Vysya community is 1 in 24, a value 4000-fold higher than the frequency of homozygous silent BChE in European and American populations.

AB - BACKGROUND: People with genetic variants of butyrylcholinesterase (EC 3.1.1.8, BChE) can have hours of prolonged apnea after a normal dose of succinylcholine or mivacurium. METHODS: Plasma samples from 226 people in the Vysya community in Coimbatore, India were tested for BChE activity. RESULTS: Nine unrelated individuals had no detectable activity. DNA sequencing revealed a novel mutation in exon 2 of the BCHE gene, responsible for the silent phenotype of human serum BChE. All silent BChE samples were homozygous for a point mutation at codon 307 (CTT→CCT), resulting in substitution of leucine 307 by proline. Western blot analysis with a monoclonal antibody showed no BChE protein in plasma. Silent BChE plasma samples had no organophosphate-reactive BChE, as measured with FP-biotin. Expression of recombinant Leu307Pro BChE in cell culture confirmed that this mutant is expressed at very low levels. The proline substitution most likely destabilizes the BChE structure and causes the protein to be misfolded and rapidly degraded. CONCLUSIONS: This is the first report of a molecularly defined BChE mutation in the Indian population. The frequency of homozygous silent BChE in the Vysya community is 1 in 24, a value 4000-fold higher than the frequency of homozygous silent BChE in European and American populations.

KW - Apnea

KW - Butyrylcholinesterase

KW - FP-biotin

KW - Mivacurium

KW - Silent variant

KW - Succinylcholine

UR - http://www.scopus.com/inward/record.url?scp=33745272832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745272832&partnerID=8YFLogxK

U2 - 10.1097/01.fpc.0000197464.37211.77

DO - 10.1097/01.fpc.0000197464.37211.77

M3 - Article

C2 - 16788378

AN - SCOPUS:33745272832

VL - 16

SP - 461

EP - 468

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 7

ER -